6 stories mentioning SHA:688278Updated 10d ago
Every FINWIRES story that references SHA:688278, newest first.
Xiamen Amoytop Biotech (SHA:688278) on Tuesday launched a convertible bond issue of 1.53 billion yuan, according to a Tuesday filing with the Shanghai bourse.Guojin Securities serves as lead underwriter, with CICC as joint lead underwriter. The bond issue carries a 30% maximum underwriter liability cap of 460.0 million yuan.Shares of the drugmaker were down 4% in recent trade.
Xiamen Amoytop Biotech (SHA:688278) plans to offer and issue convertible bonds worth 1.53 billion yuan, according to a Friday disclosure on the Shanghai bourse.The Chinese drugmaker will offer the Amoytop Convertible Bond on July 28, preferentially allotted to shareholders on the record by July 27.
Xiamen Amoytop Biotech (SHA:688278) received approval from China's National Medical Products Administration for the clinical trial of ACT201 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for chronic hepatitis B.The drugmaker's shares rose 3% at the close.
China's National Medical Products Administration accepted Xiamen Amoytop Biotech's (SHA:688278) clinical trial application for ACT201 injection, according to a Shanghai bourse filing on Thursday.The drug, an antisense oligonucleotide drug, will be used as a treatment for hepatitis B.The drugmaker's shares rose 2% during the midday trade.
Xiamen Amoytop Biotech (SHA:688278) plans to raise funds of up to 1.53 billion yuan from the issuance of convertible bonds, according to a Thursday disclosure on the Shanghai bourse.The proceeds will be used to invest in a new drug research and development project, a biotechnology innovation center project and the construction of a production line.
Xiamen Amoytop Biotech (SHA:688278) signed an exclusive license agreement with Aligos Therapeutics for pevifoscorvir sodium, used for treating chronic hepatitis B.Amoytop will pay an upfront $25 million, plus up to $85 million in regulatory and $335 million in sales milestones, plus royalties, according to a Friday filing with the Shanghai bourse.The deal covers Mainland China, Hong Kong, Macao and Taiwan.Shares of the drugmaker closed 1% lower Friday.
